Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study

INTRODUCTION: Avelumab, an antiprogrammed death ligand-1 antibody, is approved as a monotherapy for treatment of metastatic Merkel cell carcinoma and advanced urothelial carcinoma, and in combination with axitinib for advanced renal cell carcinoma. We report the efficacy and safety of first-line ave...

Descripción completa

Detalles Bibliográficos
Autores principales: Verschraegen, Claire F, Jerusalem, Guy, McClay, Edward F, Iannotti, Nicholas, Redfern, Charles H, Bennouna, Jaafar, Chen, Franklin L, Kelly, Karen, Mehnert, Janice, Morris, John C, Taylor, Matthew, Spigel, David, Wang, Ding, Grote, Hans Juergen, Zhou, Dongli, Munshi, Neru, Bajars, Marcis, Gulley, James L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481079/
https://www.ncbi.nlm.nih.gov/pubmed/32907924
http://dx.doi.org/10.1136/jitc-2020-001064

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481079/
https://www.ncbi.nlm.nih.gov/pubmed/32907924
http://dx.doi.org/10.1136/jitc-2020-001064

Ejemplares similares